Physician profile
Felix Dron
NPI 1518986561
$10,489.26
in general payments reported to CMS, 2019-2025
23 companies · $2,460 in 2025
The $2,460 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $710 · 2021: $965 · 2022: $1,134 · 2023: $1,891 · 2024: $1,862 · 2025: $2,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,065 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,065.01 |
| Education | $148.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,831.34 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $1,470.02 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,136.51 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Abbvie INC. | $999.00 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $903.33 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $850.95 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $610.52 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $560.85 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $342.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $312.62 | 2019-2024 | Spravato |
| Allergan, INC. | $281.02 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $266.04 | 2019-2025 | Trintellix |
| Almatica Pharma LLC | $264.60 | 2023-2025 | Loreev Xr, Gralise |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.31 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $174.82 | 2024-2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $64.53 | 2019-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $56.22 | 2020-2021 | |
| Corium, LLC | $46.23 | 2022 | |
| Indivior INC. | $26.86 | 2019 | |
| Alfasigma USA, INC. | $25.07 | 2020 | |
| Ironshore Pharmaceuticals INC. | $21.67 | 2023 | Jornay Pm |
| Sun Pharmaceutical Industries INC. | $21.43 | 2020 | |
| Orexo US, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Dron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.